Navigation Links
Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium
Date:10/19/2010

COLUMBIA, Md., Oct. 19 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that two abstracts on the ThermoDox® High Intensity Focused Ultrasound (HIFU) development program have been delivered via oral presentation at the MR-guided Focused Ultrasound 2010 2nd International Symposium.  The abstracts provide strong proof of concept, as well as the rationale and support for future clinical studies, which will combine ThermoDox with MR-guided HIFU for cancer indications.  The symposium is being held October 17-20, 2010 at the Westfields Marriott in Dulles, VA .  

The first abstract, titled "MR-guided High Intensity Focused Ultrasound Enhances Targeted Drug Delivery of Low Temperature Sensitive Liposomes in a Rabbit Vx2 Tumor Model," is authored by Ashish Ranjan from the National Institutes of Health, Bethesda, MD, USA.  The second abstract, titled "Thermally-mediated Localized Drug Release Using MRI-Controlled Focused Ultrasound Hyperthermia," is authored by Robert Staruch from Sunnybrook Health Sciences Centre and University of Toronto, Canada.  Additional co-authors from the two studies are from Duke University, University of Helsinki, Finland, and Philips Healthcare.  The abstracts are available on the company's website site at www.celsion.com.  

"We are delighted to expand our HIFU program to leading oncology research centers in the US, Canada and Europe," said Michael H. Tardugno, Celsion's President and Chief Executive Officer. "We hope to make a seamless transition to clinical studies in these and additional countries based on the preclinical data that has been developed through our joint research agreement with Philips Healthcare.  Celsion and Philips are now well positioned to submit our clinical program for FDA review. Assuming we have agreement, we expect to commence trials in bone cancers next year."

Dr. Nicholas Borys, Chief Medical Officer at Celsion Corporation commented, "The ultrasound and radiology communities have been very supportive of targeted drug delivery applications using MR-guided HIFU.  What started out as a few leading researchers in the US and Europe has now grown to a very large global research community. Similar to our Phase III HEAT study, we expect future HIFU clinical studies will include Asia Pacific, as many researchers from Korea, Taiwan, and China continue to approach us with new oncology applications using MR-guided HIFU."

About ThermoDox®ThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers including breast cancer. ThermoDox®, which is administered intravenously and in combination with hyperthermia, has the potential to provide local tumor control and improve quality of life. Localized mild hyperthermia (39.5-42 degrees Celsius) releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.

ThermoDox® has also demonstrated evidence of efficacy in a Phase I study for primary liver cancer. Celsion has been granted FDA Orphan Drug designation for ThermoDox® and is conducting a pivotal 600 patient global Phase III study in primary liver cancer under a FDA Special Protocol Assessment.

Additional information on ThermoDox® clinical studies for RCW breast cancer and primary liver cancer can be found at: www.clinicaltrials.gov.

ThermoDox® is a registered trademark of Celsion Corporation.

About CelsionCelsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has licensed ThermoDox® to Yakult-Honsha for the Japanese market and has a partnership agreement with Phillips Medical to jointly develop the Company's heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.

For more information on Celsion, visit our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.Investor ContactMarcy NanusThe Trout Group646-378-2927 or mnanus@troutgroup.com
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Monitoring Committee Unanimously Recommends Continuation of Celsions Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer
2. Celsion Receives SBIR Grant To Expand Its Technology Platform
3. Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer
4. Celsion Announces CFO Departure
5. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
6. Sysmex America Announces Amerinet Hematology Contract
7. iGPS Announces iGPS bios™, a New Pallet Rental Service Designed Exclusively for the Pharmaceutical and Life Sciences Industries
8. Accium BioSciences Announces $99 Sample Pricing for Its Accelerator Mass Spectrometry (AMS) Measurement Service
9. Althea Technologies Announces the Installation of a High-Speed Prefilled Syringe Line
10. Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
11. CoAxia Announces Results of SENTIS Ischemic Stroke Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... NY (PRWEB) , ... June 27, 2016 , ... ... using cutting edge technology to revolutionize the emergency ambulance transport experience for the ... are aware of how Uber has disrupted the taxi industry through the use ...
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
Breaking Medicine News(10 mins):